Rankings
▼
Calendar
ABCL Q1 2024 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena
ABCL
AbCellera Biologics Inc.
$1B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$10M
-18.4% YoY
Gross Profit
$10M
100.0% margin
Operating Income
-$55M
-551.5% margin
Net Income
-$41M
-408.0% margin
EPS (Diluted)
$-0.14
QoQ Revenue Growth
+8.4%
Cash Flow
Operating Cash Flow
-$42M
Free Cash Flow
-$66M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$333M
Stockholders' Equity
$1.1B
Cash & Equivalents
$124M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$10M
$12M
-18.4%
Gross Profit
$10M
$12M
-18.4%
Operating Income
-$55M
-$65M
+15.4%
Net Income
-$41M
-$40M
-1.2%
Revenue Segments
Research Fees
$10M
98%
License
$180,000
2%
← FY 2024
All Quarters
Q2 2024 →